About BTI

Board of Directors

Carl W. Rausch

Chief Executive Officer

August 2016 to 2017, Mr. Rausch is the CEO of Boston Therapeutics, overseeing operations in the US and in Asia. Deeply involved in the restructuring of Boston Therapeutics with an overhaul of operations for manufacture, clinical and regulatory as well as exploratory marketing. In 2014 to present, Mr. Rausch served as Managing Principal Partner of World Technology East II Ltd (WTE II), a Hong Kong based consulting firm involved with all aspects of biopharmaceutical product development, registration and licensing in various territories in Asia including Korea, Taiwan, Singapore, Myanmar, Brunei, Malaysia, Japan, China and Australia. In 2014, Mr Rausch also served as the Principal of Medical Technology Associates II (MTA II), a Delaware corporation involved in the licensing, research development as well as manufacturing and marketing of innovative technology driven high technology processes in biologics and diagnostics.

Mr Rausch has founded two biotechnology companies focused in the implementation and execution of new business opportunities related to biologic therapeutics, diagnostics and clinical research in areas of unmet medical needs. For the past decade, Mr. Rausch has served as an independent consultant for biopharmaceutical industrial clients, university based development facilities and contract research organizations for preclinical and clinical strategic management of investigative biological materials for registration with the European Medicines Agency and the US Food and Drug Administration. From 2008-2014, Mr Rausch served as Chief Scientific and Business (Consultancy) Advisor of New-a-Innovation (“NewAi”), a Hong Kong based biotechnology company involved in the drug and diagnostic development in the veterinary and human healthcare field. His main role at NewAi involved coordinating and executing preclinical and clinical trials as well as manufacturing related to global regulatory registration. Mr Rausch has been both a coach and a player coach scientifically, financially and organizationally and has been able to work as independent advisor to many biotechnology clients.

Mr. Rausch Co-founded of Biopure Corporation (“Biopure”) in 1984 and served as the Chairman, President, Vice Chairman and Chief Technical Officer of Biopure from 1984 to 2002 to 2005. Biopure grew to a market capitalization of over $1.2 billion USD in 2000 and left the leadership role in 2002. Prior years Mr. Rausch was Vice President, Preparative and Process Chromatography Division, at Millipore Corporation, and held senior positions at the chromatographic instrument supply company, Water Associates (Waters Corporation 2017), where he contributed to patented and process technology. He holds advanced degrees, M.S. degree in chemical engineering from the Massachusetts Institute of Technology and holds an M.S. degree in medical engineering and a B.S. degree in chemical engineering from Tufts University.

Conroy Chi-Heng Cheng

Director

Mr. Cheng, a Director of the Company since December 2013, serves as the Chief Executive Officer of Net Plus Company Limited. He serves as an Executive Director of Net Plus Company Limited. He has been an Executive Director of New World Development Co. Ltd. since June 2010. He serves as a Director of Chow Tai Fook Enterprises Limited. He served as an Independent Non-executive Director of Hong Kong Energy Holdings Limited (alternate name JIC Technology Co. Ltd. & China Renewable Energy Investment Limited) from July 2002 to May 2007. Mr. Cheng has a Bachelor of Arts degree majoring in Economics from the University of Western Ontario, Ontario, Canada in 1999.

S. Colin Neill

Audit Committee Chairman and Director

Mr. Neill, a Director of the Company since December 2013, became President of Pharmos Corporation in January 2008, and has served as Chief Financial Officer, Secretary, and Treasurer of Pharmos since October 2006. He held these positions through November 2012. From September 2003 to October 2006, Mr. Neill served as Chief Financial Officer, Treasurer and Secretary of Axonyx Inc., a biopharmaceutical company that developed products and technologies to treat Alzheimer's disease and other central nervous system disorders, where he played an integral role in the merger between Axonyx and TorreyPines Therapeutics Inc., a privately-held biopharmaceutical company.

Mr. Neill served as Senior Vice President, Chief Financial Officer, Secretary and Treasurer of ClinTrials Research Inc.; a $100 million publicly traded global contract research organization in the drug development business, from 1998 to its successful sale in 2001. Following that sale from April 2001 to September 2003 Mr. Neill served as an independent consultant assisting small start-up and development stage companies in raising capital. Earlier experience was gained as Vice President of Finance and Chief Financial Officer of BTR Inc., a $3.5 billion US subsidiary of BTR plc, a British diversified manufacturing company, and Vice President Financial Services of The BOC Group Inc., a $2.5 billion British owned industrial gas company with substantial operations in the health care field.

Mr. Neill served four years with American Express Travel Related Services, first as chief internal auditor for worldwide operations and then as head of business planning and financial analysis. Mr. Neill began his career in public accounting with Arthur Andersen LLP in Ireland and later with Price Waterhouse LLP as a senior manager in New York City. He also served with Price Waterhouse for two years in Paris, France. Mr. Neill graduated from Trinity College, Dublin with a first class honors degree in Business/Economics and he holds a master's degree in Accounting and Finance from the London School of Economics. He is a Certified Public Accountant in New York State and a Chartered Accountant in Ireland. Mr. Neill served on the board of Galectin Therapeutics (formerly named Pro-Pharmaceuticals, Inc.) from May 2007 to October 2011 and from April 2004 to June 2008 on the board of OXIS International, Inc.